Predictive Income Before Tax vs Total Other Income Expense Net Analysis

POAI Stock  USD 0.81  0.03  3.85%   
Predictive Oncology financial indicator trend analysis is much more than just breaking down Predictive Oncology prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Predictive Oncology is a good investment. Please check the relationship between Predictive Oncology Income Before Tax and its Total Other Income Expense Net accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Predictive Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.

Income Before Tax vs Total Other Income Expense Net

Income Before Tax vs Total Other Income Expense Net Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Predictive Oncology Income Before Tax account and Total Other Income Expense Net. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Predictive Oncology's Income Before Tax and Total Other Income Expense Net is 0.88. Overlapping area represents the amount of variation of Income Before Tax that can explain the historical movement of Total Other Income Expense Net in the same time period over historical financial statements of Predictive Oncology, assuming nothing else is changed. The correlation between historical values of Predictive Oncology's Income Before Tax and Total Other Income Expense Net is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Income Before Tax of Predictive Oncology are associated (or correlated) with its Total Other Income Expense Net. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Other Income Expense Net has no effect on the direction of Income Before Tax i.e., Predictive Oncology's Income Before Tax and Total Other Income Expense Net go up and down completely randomly.

Correlation Coefficient

0.88
Relationship DirectionPositive 
Relationship StrengthStrong

Income Before Tax

Income Before Tax which can also be referred as pre-tax income is reported on Predictive Oncology income statement and is an important metric when analyzing Predictive Oncology profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.

Total Other Income Expense Net

Most indicators from Predictive Oncology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Predictive Oncology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Predictive Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.As of now, Predictive Oncology's Tax Provision is decreasing as compared to previous years. The Predictive Oncology's current Enterprise Value is estimated to increase to about 12.6 M, while Selling General Administrative is projected to decrease to under 7.1 M.
 2021 2022 2023 2024 (projected)
Gross Profit933.7K1.0M1.1M575.4K
Total Revenue1.4M1.5M1.8M899.7K

Predictive Oncology fundamental ratios Correlations

0.180.210.320.970.620.54-0.76-0.690.320.860.730.86-0.250.590.060.610.750.310.520.870.140.730.00.250.56
0.180.410.78-0.020.58-0.090.44-0.270.55-0.270.71-0.27-0.29-0.050.320.00.230.810.28-0.260.930.63-0.390.150.06
0.210.410.810.020.430.260.1-0.330.70.00.40.00.120.110.090.00.280.790.270.010.420.370.14-0.030.38
0.320.780.810.080.540.10.28-0.30.87-0.110.75-0.11-0.070.030.16-0.070.270.980.29-0.10.770.67-0.080.020.15
0.97-0.020.020.080.490.52-0.87-0.630.120.930.570.93-0.240.59-0.020.650.710.070.450.93-0.050.60.030.260.54
0.620.580.430.540.490.51-0.28-0.850.370.40.610.4-0.20.710.690.460.840.620.870.410.340.58-0.170.180.57
0.54-0.090.260.10.520.51-0.65-0.810.10.670.10.670.010.850.40.520.80.150.750.67-0.25-0.010.170.190.66
-0.760.440.10.28-0.87-0.28-0.650.550.17-0.98-0.11-0.980.12-0.660.02-0.63-0.620.28-0.41-0.980.48-0.16-0.16-0.13-0.58
-0.69-0.27-0.33-0.3-0.63-0.85-0.810.55-0.23-0.63-0.43-0.630.25-0.91-0.61-0.71-0.99-0.37-0.94-0.64-0.05-0.330.16-0.38-0.81
0.320.550.70.870.120.370.10.17-0.23-0.040.68-0.04-0.060.080.15-0.10.220.850.26-0.040.520.5-0.08-0.140.17
0.86-0.270.0-0.110.930.40.67-0.98-0.63-0.040.281.0-0.160.680.010.660.69-0.10.471.0-0.320.330.130.160.63
0.730.710.40.750.570.610.1-0.11-0.430.680.280.28-0.230.180.090.210.470.730.340.280.70.93-0.150.220.18
0.86-0.270.0-0.110.930.40.67-0.98-0.63-0.041.00.28-0.160.680.010.660.69-0.10.471.0-0.320.330.130.150.63
-0.25-0.290.12-0.07-0.24-0.20.010.120.25-0.06-0.16-0.23-0.16-0.15-0.04-0.42-0.27-0.07-0.17-0.18-0.26-0.20.94-0.25-0.4
0.59-0.050.110.030.590.710.85-0.66-0.910.080.680.180.68-0.150.660.620.920.110.930.69-0.310.07-0.060.190.72
0.060.320.090.16-0.020.690.40.02-0.610.150.010.090.01-0.040.660.130.560.30.810.01-0.02-0.04-0.21-0.060.35
0.610.00.0-0.070.650.460.52-0.63-0.71-0.10.660.210.66-0.420.620.130.72-0.040.530.69-0.110.21-0.250.680.78
0.750.230.280.270.710.840.8-0.62-0.990.220.690.470.69-0.270.920.560.720.330.920.710.020.38-0.150.370.79
0.310.810.790.980.070.620.150.28-0.370.85-0.10.73-0.1-0.070.110.3-0.040.330.39-0.090.740.64-0.10.010.21
0.520.280.270.290.450.870.75-0.41-0.940.260.470.340.47-0.170.930.810.530.920.390.48-0.010.21-0.160.180.67
0.87-0.260.01-0.10.930.410.67-0.98-0.64-0.041.00.281.0-0.180.690.010.690.71-0.090.48-0.310.330.110.20.65
0.140.930.420.77-0.050.34-0.250.48-0.050.52-0.320.7-0.32-0.26-0.31-0.02-0.110.020.74-0.01-0.310.67-0.320.14-0.11
0.730.630.370.670.60.58-0.01-0.16-0.330.50.330.930.33-0.20.07-0.040.210.380.640.210.330.67-0.090.210.14
0.0-0.390.14-0.080.03-0.170.17-0.160.16-0.080.13-0.150.130.94-0.06-0.21-0.25-0.15-0.1-0.160.11-0.32-0.09-0.2-0.27
0.250.15-0.030.020.260.180.19-0.13-0.38-0.140.160.220.15-0.250.19-0.060.680.370.010.180.20.140.21-0.20.33
0.560.060.380.150.540.570.66-0.58-0.810.170.630.180.63-0.40.720.350.780.790.210.670.65-0.110.14-0.270.33
Click cells to compare fundamentals

Predictive Oncology Account Relationship Matchups

Predictive Oncology fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets22.4M13.1M43.8M25.7M14.4M9.5M
Short Long Term Debt Total5.5M5.9M879.3K180.3K2.9M1.9M
Other Current Liab2.4M2.9M1.4M2.1M1.6M1.6M
Total Current Liabilities10.9M9.3M3.2M3.9M4.0M4.0M
Total Stockholder Equity11.2M2.6M40.3M21.8M8.3M5.0M
Property Plant And Equipment Net2.2M5.2M3.3M2.0M4.0M4.2M
Current Deferred Revenue40.4K53.0K187.0K602.1K308.1K323.5K
Net Debt5.4M5.2M(27.3M)(21.9M)(5.9M)(5.6M)
Retained Earnings(82.5M)(108.4M)(128.0M)(153.8M)(167.8M)(159.4M)
Accounts Payable3.2M1.4M1.0M943.5K1.3M1.1M
Cash150.8K678.3K28.2M22.1M8.7M4.7M
Non Current Assets Total21.6M11.5M14.3M2.4M4.3M4.1M
Cash And Short Term Investments150.8K678.3K28.2M22.1M8.7M4.7M
Common Stock Total Equity69.4K140.9K40.6K198.0K178.2K275.4K
Common Stock Shares Outstanding143.5K597.5K2.7M3.6M4.0M4.2M
Liabilities And Stockholders Equity22.4M13.1M43.8M25.7M14.4M9.5M
Non Current Liabilities Total270.3K1.1M265.1K86.1K2.2M2.3M
Other Current Assets160.2K289.5K513.8K526.8K521.7K263.4K
Other Stockholder Equity93.7M110.8M167.6M174.8M176.0M184.8M
Total Liab11.1M10.4M3.5M4.0M6.1M4.6M
Property Plant And Equipment Gross2.2M3.8M3.3M4.9M7.6M7.9M
Total Current Assets798.3K1.5M29.5M23.4M10.1M5.5M
Short Term Debt5.3M5.0M639.7K188.5K667.8K634.4K
Intangible Assets3.6M3.4M4.0M253.9K252.5K239.8K
Common Stock40.6K198.0K656.1K787.6K40.6K38.6K
Net Receivables297.1K256.9K354.2K331.2K333.7K270.7K
Inventory190.2K289.5K387.7K430.5K494.4K299.1K
Non Currrent Assets Other(21.6M)116.3K167.1K75.6K124.1K130.3K
Accumulated Other Comprehensive Income(273.8K)(358.8K)(771.6K)(792.0)(712.8)(748.44)
Capital Surpluse57.4M63.0M93.7M110.8M127.5M70.3M
Property Plant Equipment2.2M5.2M3.3M2.0M2.4M1.7M
Net Tangible Assets(8.1M)(3.6M)29.4M21.5M24.7M26.0M
Net Invested Capital16.0M7.1M40.3M21.8M8.4M15.4M
Net Working Capital(10.1M)(7.8M)26.2M19.5M6.1M5.2M
Capital Stock76.4K198.8K656.9K788.4K41.4K39.3K

Currently Active Assets on Macroaxis

When determining whether Predictive Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Predictive Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Predictive Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Predictive Oncology Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Predictive Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.
You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Predictive Oncology. If investors know Predictive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Predictive Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.96)
Revenue Per Share
0.416
Quarterly Revenue Growth
(0.43)
Return On Assets
(0.56)
Return On Equity
(1.49)
The market value of Predictive Oncology is measured differently than its book value, which is the value of Predictive that is recorded on the company's balance sheet. Investors also form their own opinion of Predictive Oncology's value that differs from its market value or its book value, called intrinsic value, which is Predictive Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Predictive Oncology's market value can be influenced by many factors that don't directly affect Predictive Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Predictive Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Predictive Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Predictive Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.